RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Antiphospholipid and Antinuclear Antibodies in Children with Idiopathic Epilepsy: A 2-Year Prospective Study

      한글로보기

      https://www.riss.kr/link?id=A106609500

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Background and Purpose The high prevalence of antiphospholipid antibodies (aPL) and antinuclear antibodies (ANA) in patients with epilepsy may be associated with either the disease itself or the antiepileptic treatment. The purpose of this prospective...

      Background and Purpose The high prevalence of antiphospholipid antibodies (aPL) and antinuclear antibodies (ANA) in patients with epilepsy may be associated with either the disease itself or the antiepileptic treatment. The purpose of this prospective study was to determine the prevalence of aPL and ANA in children with idiopathic epilepsy before and during treatment with antiepileptic drugs.
      Methods aPL, including both anticardiolipin and anti-β2-glycoprotein I antibodies, and ANA statuses were determined in 40 healthy children, 30 children treated with sodium valproate (VPA) monotherapy, and 20 children treated with carbamazepine (CBZ) monotherapy before and at 6, 12, and 24 months after treatment initiation.
      Results Fifteen children (50%) in the VPA-treated group and 7 (35%) in the CBZ-treated group showed positivity for aPL before treatment initiation, compared with only 4 of the 40 controls. Nine children (30%) in the VPA-treated group and 4 (20%) in the CBZ-treated group showed positivity for ANA before treatment initiation, compared with only 2 of the 40 controls. The subgroup analysis found nonsignificant associations at the different time points regarding the positivity of all of the autoantibodies. Only patients treated with VPA had a significantly decreased risk of aPL positivity after 6 months of treatment.
      Conclusions The increased prevalence of autoantibodies in children with idiopathic epilepsy is strongly associated with the disease itself.

      더보기

      참고문헌 (Reference)

      1 Liimatainen S, "The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures" 16 : 134-141, 2009

      2 Arnson Y, "The antiphospholipid syndrome as a neurological disease" 40 : 97-108, 2010

      3 Constantin T, "Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy" 15 : CR164-CR169, 2009

      4 Cimaz R, "Prevalence of anti-cardiolipin, anti-β2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy" 43 : 52-59, 2002

      5 Verrot D, "Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy" 103 : 33-37, 1997

      6 Angelini L, "Partial seizures associated with antiphospholipid antibodies in childhood" 29 : 249-253, 1998

      7 Agmon-Levin N, "International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies" 73 : 17-23, 2014

      8 Eriksson K, "High prevalence of antiphospholipid antibodies in children with epilepsy : a controlled study of 50 cases" 46 : 129-137, 2001

      9 Julian T, "Gluten sensitivity and epilepsy : a systematic review" 266 : 1557-1565, 2019

      10 Specchio N, "Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis" 32 : 51-56, 2010

      1 Liimatainen S, "The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures" 16 : 134-141, 2009

      2 Arnson Y, "The antiphospholipid syndrome as a neurological disease" 40 : 97-108, 2010

      3 Constantin T, "Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy" 15 : CR164-CR169, 2009

      4 Cimaz R, "Prevalence of anti-cardiolipin, anti-β2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy" 43 : 52-59, 2002

      5 Verrot D, "Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy" 103 : 33-37, 1997

      6 Angelini L, "Partial seizures associated with antiphospholipid antibodies in childhood" 29 : 249-253, 1998

      7 Agmon-Levin N, "International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies" 73 : 17-23, 2014

      8 Eriksson K, "High prevalence of antiphospholipid antibodies in children with epilepsy : a controlled study of 50 cases" 46 : 129-137, 2001

      9 Julian T, "Gluten sensitivity and epilepsy : a systematic review" 266 : 1557-1565, 2019

      10 Specchio N, "Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis" 32 : 51-56, 2010

      11 Dlott JS, "Drug-induced lupus anticoagulants and antiphospholipid antibodies" 14 : 71-78, 2012

      12 Rumsey DG, "Diagnosis and treatment of antiphospholipid syndrome in childhood : a review" 67 : 34-40, 2017

      13 Graf J, "Central nervous system manifestations of antiphospholipid syndrome" 43 : 547-560, 2017

      14 Brey RL, "Antiphospholipid antibodies and the brain : a consensus report" 20 : 153-157, 2011

      15 Peltola JT, "Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders" 109 : 712-717, 2000

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2012-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2011-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2008-01-01 평가 SCIE 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 2.07 0.25 1.55
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      1.25 1.08 0.497 0.02
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼